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ABSTRACT 
Several debilitating neurological disorders, such as Alzheimer's disease, stroke, and spinal 
cord injury, are characterized by the damage or loss of neuronal cell types in the central 
nervous system (CNS). Human neural progenitor cells (hNPCs) derived from human 
pluripotent stem cells (hPSCs) can proliferate extensively and differentiate into the various 
neuronal subtypes and supporting cells that comprise the CNS. As such, hNPCs have 
tremendous potential for disease modeling, drug screening, and regenerative medicine 
applications. However, the use hNPCs for the study and treatment of neurological diseases 
requires the development of defined, robust, and scalable methods for their expansion and 
neuronal differentiation. To that end a rational design process was used to develop a 
vitronectin-derived peptide (VDP)-based substrate to support the growth and neuronal 
differentiation of hNPCs in conventional two-dimensional (2-D) culture and large-scale 
microcarrier (MC)-based suspension culture. Compared to hNPCs cultured on ECMP-
based substrates, hNPCs grown on VDP-coated surfaces displayed similar morphologies, 
growth rates, and high expression levels of hNPC multipotency markers. Furthermore, 
VDP surfaces supported the directed differentiation of hNPCs to neurons at similar levels 
to cells differentiated on ECMP substrates. Here it has been demonstrated that VDP is a 
robust growth and differentiation matrix, as demonstrated by its ability to support the 
expansions and neuronal differentiation of hNPCs derived from three hESC (H9, HUES9, 
and HSF4) and one hiPSC (RiPSC) cell lines. Finally, it has been shown that VDP allows 
for the expansion or neuronal differentiation of hNPCs to quantities (>1010) necessary for 
drug screening or regenerative medicine purposes. In the future, the use of VDP as a 
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defined culture substrate will significantly advance the clinical application of hNPCs and 
their derivatives as it will enable the large-scale expansion and neuronal differentiation of 
hNPCs in quantities necessary for disease modeling, drug screening, and regenerative 
medicine applications. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Motivation 
With the aging population of United States, an ever increasing number of Americans are 
afflicted from neurodegenerative diseases. Neurodegenerative diseases are characterized 
by gradual and progressive loss in structure and function of neurons and other supporting 
cells of brain which leads to a nervous system dysfunction.  Each of the neurodegenerative 
disease such as Alzheimer’s disease (AD), Parkinson’s diseases (PD) and Amyotrophic 
Lateral Sclerosis (ALS), involves neurodegeneration of cerebral cortex, substantia niagra, 
and spina cord, respectively [1]. Among all, only few occur to be as a familial condition 
(about or less than 10%) i.e. supporting a genetic basis like these diseases may run as an 
autosomal dominant condition within family, such is the case in Huntington’s disease 
(HD). Most of the neurodegenerative diseases are diagnosed primarily to be sporadic where 
there is minimum genetic contribution and variety of factors are involved such as 
environmental factors, exposure to toxicity etc. [2]. This may lead to single or various 
mutations in genes that are directed to certain protein and pathways of nervous system, like 
mutations in the β-amyloid precursor protein causes AD; in α-synuclein causes PD; and in 
microtubule-associated protein tau causes frontotemporal dementia (FTD). Many of these 
neurodegenerative disorders often shows dichotomy between sporadic and familial forms 
(like AD, PD and ALS) [3]. 
According to National Institute of Neurological Disorders and Stroke, there are 600 
different types of Neurological disorders and 50 million Americans are affected each year. 
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Thus Neurological disorders accounts for an unaccountable personal toll and an annual 
economic cost of hundreds of billions of dollars in medical expenses and lost productivity 
[4].  From recent statistics of 2015, 5.3 million Americans have AD  from which 5.1 million 
individuals are 65 and older whereas the rest of the 200,000 individuals are under 65 having 
younger-onset Alzheimer’s [5]. Nearly 44 million people worldwide have AD or other 
related Dementia and this is most prevalent in Europe followed by North
America. The cost of caring for AD patients in U.S was estimated to be $226 billion in 
2015 and the global cost for the same has been accounted to be around $605 billion [6]. 
Parkinson’s disease (PD) affects up to 6.3 million people worldwide [7] and 1 million 
people in the US with cost of medical treatment around $25 billion [8]. 
Even though the diagnosis of the Neurodegenerative diseases have made immense progress 
in last four decades but the rightful cure for the same is still worked on. With these fast 
growing incidences of Neurodegenerative diseases and large investments in medical cost, 
the limitation of only a symptomatic treatment vs the actual therapies is still a big loop hole 
for the Neuroscience research. General protocol for the treatments that are able to 
ameliorate the symptoms of various neurodegenerative diseases involve: i) intake of 
symptomatic drugs, like in PD, the intake of Levodopa, a precursor of dopamine, gets 
converted into dopamine by dopa carboxylase and reduces rigidity, bradykinesia and 
tremors which are the most frequent symptoms of PD [9], ii) Use of battery implanted deep 
brain stimulations, that involves delivery of precise electrical signals to specific deep 
anatomical structures of the CNS and aims to alter or modulate the neural functions in order 
to achieve a therapeutic effect [10], iii) injecting Neurotrophic factors, that have the ability 
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to regulate differentiation and to support growth during development of the nervous 
system, is being progressed lately because they have been documented to prevent cell death 
and maintain cellular function of the nervous system [11], iv) Cell based therapies as a 
potential mainstream medicine, which involves administration of stem cells into the 
patients which can differentiate into the different cell types that may be damaged or dead 
due to the neurodegenerative disease. Human Pluripotent Stem cells (hPSCs) have the 
ability to extensively proliferate and differentiate into various cell types of the CNS such 
as, neurons, glial cells including astrocytes, oligodendrocytes etc. Thus, stem cells holds 
an utmost importance in the therapeutics of neurodegenerative diseases such as AD, PD, 
ALS, etc.  
However, the other three treatments have their own limitations. The symptomatic drugs, as 
the name suggest, only aim to give temporary relief to the patients based on the symptoms. 
In AD, all the class of drugs approved for the treatment of memory loss, a symptom of AD, 
belongs to cholinesterase inhibitors. Cholinesterase inhibitors prevents breakdown of  
acetylcholine, a chemical messenger important in learning and memory function, and 
delays worsening of the symptoms for 6-12 months [12]. The deep brain stimulations in 
PD and Dystonia patients is performed by implanting a neurostimulator in collarbone 
which is connected to the brain via tiny electrodes that carry electrical signals. Although it 
might carry drawbacks such as cranial bleeding, cognitive dysfunction [13], [14]. In the 
neurotrophin based therapies, the family of neurotrophins like nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 
(NT4) is involved. Each of these factors binds to the tyrosine receptor kinase (Trk) family: 
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like NGF binds to TrkA, BDNF and NT4 binds to TrkB, and NT3 binds to TrkC, and 
theycan respond to apoptotic pathway which is initiated by binding to neurotrophin 
receptors. NGF and BDNF are dominant neurotrophins of the peripheral nervous system 
(PNS) and CNS, respectively.  Although there is strong ground for using neurotrophins to 
degenerating neurons as potential way to restore neuronal activity in neurodegenerative 
diseases, delivering neurotrophins to brain is still an insignificant approach. Moreover, the 
diseases of thee CNS are difficult to treat due to the presence of the blood brain barrier 
(BBB) making it impossible for the large proteins and compounds to cross from blood into 
the brain. The neurotrophins are large, polar molecules that cannot cross the BBB and thus 
should be injected directly into the CNS making it even more difficult. 
On the other hand, cell based therapies and gene transfer to the diseased and injured brain 
have emerged as a promising approach for the therapeutics of the neurodegenerative 
diseases. It has the potential to replace the diseased, dead, or lost neurons of the CNS and 
restore the neural functions thus acting beyond a short term symptomatic effect for 
neurological diseases. For successful development of the stem-cell based therapies, clinical 
roadmaps need to be defined. One of the major issues occurring in the basic clinical 
research before these therapies can be tested into humans and animal models are the type 
of substrate used for stem cell culture. Also, to understand the full potential of stem cells 
in cell based therapies, there is a need for the development of defined, robust and scalable 
culture conditions for their expansion and neuronal differentiation.  
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1.2. Neurodegeneration  
Neurodegeneration is a topic that is mentioned actively everywhere and thus it is safe to 
assume its definition being familiar to everyone. Neurodegeneration is any pathological 
condition which results in damage, death, or loss of function, structure of the nerve cells 
or the nervous system itself. Generally, it represents pathologies which are restricted to the 
nervous system. Some of the most talked about neurodegenerative disorders are 
Alzheimer’s Disease (AD), Parkinson’s Diseases (PD), Huntington’s Disease (HD)  and 
Amyotrophic Lateral Sclerosis (ALS).  
One of the major causes of developing a Neurodegenerative diseases is increasing age. 
Lately, the growth rate of the 65 aged and older population has exceeded the 
overpopulation as a whole which means that the proportion of the old aged will double and 
so will be the proportion of the people with neurodegenerative disease [15]. Thus it is of 
utmost importance that an effective preventive strategy is developed for treatment or else 
we will just have to keep expecting the values and figures of the people affected gets higher 
with passing time. And it cannot be ignored that nearly all the neurodegenerative disorders 
shorten the life span of the individuals affected besides the availability of the medicines 
that alleviate the symptoms. Neurodegenerative diseases are generally not attributed to 
single or multiple genes but are at times far more complicated involving number of known 
and unknown signaling pathways, protein aggregation, stress, etc.  
Despite the ongoing research and neuropathological findings, sporadic neurodegenerative 
diseases comprises of the cases that we are still far away from understanding their 
molecular etiologies. To support this, we know that AD is caused bythe accumulation of 
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β-amyloid proteins and Tau proteins still we know only little about the sporadic form of 
AD. Following the disease study in the relatives or sibling of such sporadic AD patients, 
raises a possibility of involvement of genetic factors in this [16]. 
1.2.1 Alzheimer’s Disease 
Alzheimer’s disease is associated with the progressive aggregation and accumulation of 
insoluble fibrous material- extracellular β amyloid protein and intraneuronal 
neurofibrillary tangles which are generally not found in the CNS [17]. This results in 
dementia that affects the memory, thinking and behavior of the individual. The β-amyloid 
accumulation interferes with the neuron-neuron communication and thereby hindering the 
synapses. The neurofibrillary tangles, caused by Tau proteins block the nutrient transport 
within the neuron which eventually results in cell death. 
The genetical pathology of this relates to three genes: amyloid precursor protein (APP), 
presenelin 1 (PS1) and presenelin 2 (PS2). Based on the ‘amyloid-cascade hypothesis’, 
amyloid β is produced in normal individuals and follows the non-amyloidogenic pathway 
where APP undergoes a sequential cleavage by alpha and gamma-secretases, respectively, 
which generates water soluble and nonpoisonous peptide different from Amyloid β. But in 
case of AD, Amyloid β, an insoluble peptide, is formed as APP is cleaved by beta secretases 
followed by gamma-secretase by undergoing the amyloidogenic pathway (Figure 1A) [18], 
19]. Gamma-secretase is a multiprotein complex that is made up of PS1 and PS2 proteins. 
Tau protein aggregation in the neurons are generated due to excessive or abnormal 
phosphorylation which results in the transformation of normal Tau into PHF-tau (paired 
helical filament) and Neurofibrillary tangles (NFTs) (Figure 1B)[20]. 
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Figure 1 (A) The Amyloid-Cascade Hypothesis for Familial AD[18],[19]. (B) The Tau 
Hypothesis[20]. 
The incidence of AD has also been reported due Apolipoprotein E (ApoE) gene. There are 
three types of ApoE: E2, E3 and E4, of which E4 is primarily associated with AD whereas 
the other two are known to provide protection against AD.  
Once AD develops in an individual, the cholinergic neurons and nerve synapses are 
affected which starts to then degenerate and gradually dies. It starts in the transentorhinal 
cortex and then spreads to the entorhinal cortex, the hippocampus and the cerebral cortex 
[21]. 
B 
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1.2.2 Parkinson’s Disease 
Parkinson’s disease is the second most prevalent neurodegenerative disease in US affecting 
1 million people every year [21]. It is defined by the loss of dopaminergic neurons within 
substantia niagra affecting ventral component of the pars compacta in particular. Dopamine 
is a chemical messenger responsible for transmitting signals between the substantia niagra 
and corpus striatum to produce movements in the body. Thus, in PD, loss of dopamine 
results in abnormal nerve patters thereby causing impaired movements [22]. The initial 
stages are generally pre-symptomatic but as the disease progresses, the substantia niagra, 
parts of mid brain and basal forebrain gets involved.  This staging is based on the Lewy 
bodies and Lewy neurites which are pathological hallmark for PD. Lewy bodies are 
immunoreactive inclusions or deposits of α-synuclein and Lewy neurites are nerve cell 
processes that contain aggregates of α-synuclein and are most numerous in CA2/3 region 
of hippocampus and substantia niagra [23]. It was later discovered that by administration 
of oral drug ‘Levodopa’ could replenish the dopaminergic neurons and alleviates most of 
the symptoms associated with PD. Over time it was discovered that during its treatment 
over the years, individuals develop involuntary movements, dyskinesias [24]. 
Currently the research for PD is focused towards prevention of degeneration of 
dopaminergic neurons, still all the current treatments are symptomatic and none can halt 
this degeneration. Recent studies are focused on three cellular dysfunctions that maybe 
important in the pathogenesis of PD: oxidative stress, mitochondrial respiration defect and 
abnormal aggregation [25].  Animal models have been used to study the role of α-synuclein 
in PD. Eleonora Maries et al. described this by injecting neurotoxin MPTP in mice models. 
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MPTP effect by inhibiting the mitochondrial complex I which results in generation of 
reactive oxidative species, accumulation of α-synuclein thereby leads to cell death [26]. 
1.2.3. Huntington’s Disease 
Huntington’s Disease (HD) is an autosomal-dominantly inherited disease which is caused 
due to mutation in exon 1 of huntingtin (HTT) gene on Chromosome 4 resulting in the 
repeats of the trinucleotide sequence CAG. The abnormal elongation of the CAG repeats 
expands the polyglutamine stretch of HTT protein which then becomes proportionally toxic 
and eventually leads to neurodegeneration [27],[28]. The proteolysis post mutation releases 
toxic N-terminal fragment of the HTT and this fragment forms protein aggregates in 
nucleus, cytoplasm and processes of neurons. Generally the exon 1 of HTT gene has 3-30 
repeats in an individual but if the number exceed 35, the chances of pertinence of the 
disease becomes likely with chances being definitive at  ≥39 CAG repeats [29]. The length 
of these repeats have shown to have a direct  relation with the age, if the repeats are higher 
(50-200), the symptoms for HD will start to progress from early age, where as if the repeats 
are 39-50, the first signs appear at 35-40 years of age [30]-[32].  
Being inherent, HD has no sporadic forms and since it occurs only in humans, to study this 
animal models needs to be genetically modified. M. Flint Beal et al. presented a brief 
overview of the transgenic mouse models for HD to understand its therapeutics better [33]. 
The characteristic symptoms of the disease have reflected manifestations in the motor and 
cognitive functions. Postmortem studies of the HD patient’s brain indicates a 30% 
reduction in the total brain weight, neuronal loss in the caudate-putamen, collectively 
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known as striatum and are the major components of the basal ganglia, and the globus 
pallidus [34]. 
1.2.4 Amyotrophic Lateral Sclerosis (ALS) 
ALS is a fatal neurodegenerative disease characterized by progressive degeneration of 
motor neurons. ‘Amyotrophic’ means muscle atrophy, fragility, vellication that represents 
the disease of motor system and ‘lateral sclerosis’ refers to the hardening of the lateral 
columns of the spinal cord which is followed by degeneration of the corticospinal tracts 
[35], [36].The neuropathological findings on ALS patients reveal degeneration ad loss of 
the large anterior horn cells of the spinal cord and lower cranial motor neurons of the brain 
stem. The striated muscles show denervation atrophy and the upper motor neurons in the 
motor cortex are also affected [37].  
 About 5-10% of ALS is familial following Mendelian pattern of inheritance and so far, 13 
genes and loci corresponding to the defect have been identified. To name a few, SOD1, 
TARDBP (also known as TDP-43), FUS, ANG and OPTN cause a typical clinical 
phenotype. Mutations in SOD1 accounts for 20% of the familial ALS [38], [39]. The TDP-
43 positive mutations have shown to overlap between ALS and fronto-temporal dementia 
(FTD) [40], this has given a positive approach to look at the genetic contributions of ALS.  
The lack of effective therapies for all these neurological diseases are however creating a 
burden on the society [40]. Despite the destructive nature of the above mentioned diseases 
with respect to the number of people affected, billions of dollars are spent yearly for the 
healthcare but stunningly there is still lack of treatment with no cure available for any of 
these as of now. Even after decades of research and with no effective treatments available, 
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cell based therapies have emerged as an attractive option with applications of stem cells 
rapidly coming into play.  
1.3 Stem Cells and Therapies 
Stem cells can be defined by their ability to self –renew, i.e. to duplicate into cells without 
any loss in the developmental potential of the cell and the potency to develop into multiple 
different cell types. In many tissues they act as an internal repair system, they keep dividing 
into various cell types within that tissue as long as the individual lives. When a stem cell 
divides, each new cell generated has the potential to either remain as a stem cell or become 
a cell of particular type [41]-[46].  
There are two types of stem cells- embryonic stem cells and non-embryonic stem cells (also 
known as adult stem cells). Embryonal Stem Cells (ESCs) are derived from the totipotent 
inner cell mass of the 8-16 cell stage of embryonic blastocyst and are capable of unlimited 
proliferation and differentiation into various cell types of the organism [47]. This 
pluripotency of the ESCs is maintained and controlled by a conserved network of 
transcription factors and signaling pathways.  In other words, they can develop into more 
than 220 cell types of an adult organism when provided sufficient and necessary 
stimulation and nutrients for the specific cell type. ESCs can be maintained in culture 
systems as undifferentiated cells or can be induced to be differentiated into different 
lineages [48], [49].  
Adult stem cells are multipotent stem cells which act as the repair system for the body in 
replacing the damaged or the dead cells or tissues. They have the property of self-renewal 
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and multipotency. They have ability to generate in to cell types of different progenies like 
Hematopoietic stem cells, mesenchymal stem cells, pancreatic stem cells etc. [50]. 
In 2006, Yamanaka and Takahashi induced pluripotency in mouse embryonic and adult 
fibroblasts by introducing four transcription factors, Oct3/4, Sox2, Klf4, and c-Myc and 
called these cells as induced pluripotent stem cells (iPSCs) [52]. His study was a major 
breakthrough in stem cell research as now normal cells could be induced back to 
pluripotency state. Current research with induced pluripotent stem cells (iPSCs) which are 
derived from differentiated cells have potentially expanded the resource of stem cells for 
therapeutics and research. 
IPS cells are adult cells that are reprogrammed into the pluripotent state like ESCs. They 
can be differentiated into any cells types of the body. Figure 2 sums up briefly the different 
cell types that ESC ad iPSCs can be differentiated into [53].  
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Figure 2. Stem Cell Differentiation Pathway: ESCs and iPSCs can be Differentiated 
into Various Cells of the Body by Inducing the Specific Pathways upon Introducing 
Respective Transcription Factors [54]. 
 
Stem cells are not only a promising approach for regenerative medicine and cell based 
therapies but also for drug discovery and development process. For diseases such as various 
neurodegenerative diseases, using stem cell based in vitro models have a given a new ray 
of hope in order to understating the disease better.  Pluripotent stem cells because of their 
differentiation capabilities, allow researchers to follow disease progression and gain 
valuable insight of the pathophysiology of the disease by obtaining the relevant cell 
populations.  Because of their capacity to self-renew, they also facilitate cell based genetic 
or drug screening and are considered as inexhaustible, scalable and physiologically native 
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material for experiments. To sum up, stem cells have been actively used in i) disease 
modelling, ii) drug screening, and iii) cell based therapies [55],. Figure 3 gives an overview 
of the potential use of iPSCs in neurodegenerative diseases with AD as a model. 
 
Figure 3. A Brief Overview of the use of iPSCs in Therapeutics of Neurodegenerative 
Diseases- AD and PD[65]. 
 
1.3.1 Stem Cells for Disease Modelling 
Currently, medical research relies mostly on having appropriate model systems to study 
the diseases in order to develop therapies. Transgenic animal models, particularly mice 
models have allowed us to study many complex diseases in vivo. However, in vivo models 
hold several drawbacks such as: i) age related differences between animals and humans, ii) 
no help of in vivo models for sporadic forms of diseases iii) species differences as animals 
are not humans[56],[57]. Disease models serve as a platform to understand the biochemical 
mechanisms of normal phenotypes and process in comparison to the disease state. 
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Particularly in complex, multigenic diseases, molecular studies leads to a greater 
understanding of the disease and thus has more targeted approaches for therapies [58]-[60]. 
Disease modelling using pluripotent stem cells involve two parameters: their 
differentiation into pathologically relevant populations and their ability to sum up the key 
aspects of the disease [61]. Diseases in which the particular cell types are highly 
inaccessible, such as various neurodegenerative diseases, are of great interest of research 
through stem cell based disease modelling. Various disease models, using iPSCs, for 
neurodegenerative diseases such as PD , AD , HD and ALS have been developed [62]-[64].  
The iPSC technology is very promising and has the potential to model and treat the 
neurodegenerative diseases. Patient derived iPSCs can be reprogrammed to affected 
neuronal subtypes through in vitro differentiation or using reprogrammed iPSCs using gene 
targeting to repair disease causing mutation. Another key potential of this is to use these 
affected neuronal subtypes for drug screening about which we will discuss shortly [65]. 
1.3.2 Stem Cells Drug Screening and Toxicity 
The historical methods being followed for efficient and efficacious drug testing lack 
approach to understand the mechanisms of toxicity, pathogenesis of several diseases and 
biological and biochemical control of cellular processes in complex diseases [66]. By 
exposing new drugs, for drug screening and toxicity testing, into ESCs or iPSCs derived 
3D cultures can reveal their ability to study efficacious or toxic changes because of drug 
within the structure. Several human ESCs and human iPSCs (collectively termed as hPSCs) 
have been reportedly commercialized and used for drug screening and drug testing. HiPSCs 
derived cardiomyocytes have been used for cardiotoxicity testing [67], hPSCs derived 
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hepatocytes have been generated and used for drug testing and screening [68]. Because 
these cells are derived from human source, the hPSCs will provide a valuable information 
about the drug safety, efficacy and any possible toxicity.  
However, drug screening using hPSCs is still in its infancy. Neurodegenerative diseases 
provide a vast source for drug exploration due to the complexity of the diseases involved 
with the CNS. But now progress is being made with phenotypic evolution of iPSCs [69]. 
Lately, iPSCs have been developed from familial forms of ALS and necessary 
complementary assays and single cell longitudinal studies have been performed to 
understand the reduced life span of motor neurons. Through this, two compounds, 
tryphostin 9 and kenpaullone were identified as motor neuron protectors [70], [71]. 
Even though hPSCs have been used successfully for drug screening and toxicity testing, 
there are still many challenges that needs to be overcome, such as, cost reduction, 
standardizing the method of high throughput screening, improvement in cell maturation 
towards adult phenotypes, and standardizing the protocol for production of large cell 
numbers to be used in the study [72]-[76].   
1.4 Stem Cell Therapies for Neurodegenerative Diseases 
hPSCs have been considered as the potential treatments for various diseases to restore the 
tissue function either as integrated participants in the target tissue or as vehicles that deliver 
complex signals [77]. The objective of stem cell based cellular therapies are to utilize stem 
cells to treat the disease or injury.  In recent years, clinical trials with stem cells have taken 
research into entire new direction. hESCs have begun to make their way to the Phase I 
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clinical trials with Oligodendrocyte precursor cells derived from hESCs for use in thoracic 
spinal cord injury [78]. 
Neurodegenerative diseases create an enormous burden on the societies as there are still no 
effective treatments available for them. In humans, the existence of Neural stem cells 
(NSCs) with multipotent properties have been reported in the brain [79]. It was evidenced 
in a group of cancer patients that were infused with bromodeoxyuridine for diagnostic 
purposes, who later died, that new neurons are continuously being generated in adult 
human CNS [80]. But then there is only a limited capacity of these NSCs to repair the 
diseased or injured CNS [81]-[83].  
The cellular replacement for neurodegenerative diseases involve deriving the specific cell 
types that are lost, diseased or dead and grafting them into the affected area of the CNS. 
The transplanted neurons may then get integrated into the neural work to function 
normally. Also, the grafted stem cells may also act as enrichment source to the diseased 
cells  and may support them providing them with various neurotrophic factors, removing 
toxic factors and creating a neural network to support the matrix around the affected matrix 
[84]-[87]. The appropriate cellular therapy is based on the type of neurodegenerative 
disease as each disease has its specific pathology. However, there are still many obstacles 
that need to be looked upon before clinical application of stem cell therapy in 
neurodegenerative diseases such as: i) it is still uncertain as to what kind of stem cells can 
be the ideal source of cellular grafts, ii) the mechanism by which the transplantation of 
stem cells can lead to the functional recover and structural reorganization of the CNS must 
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be understood, iii) cost effectiveness of the stem cell culture so that required amount of 
cells can be cultured for patients effectively.  
1.5 Role of Extra Cellular Environment on Stem Cell Culture 
It has been actively shown that stem cell development and differentiation require a niche, 
i.e. a microenvironment housing stem cells that regulates their self-renewal and fate [88] – 
[90]. The regulatory signals for this are provided by niche cells, soluble factors, and the 
extracellular matrix (ECM). Many such soluble factors such as FGFs, BMPs, Wnt have 
previously shown to regulate the stem cell behavior but the role of the ECM is still poorly 
understood.  The ECM provides a scaffold for cellular support and a microenvironment 
that can trigger regulating signals that support stem cell proliferation, expansion, migration 
and differentiation [91]-[92]. 
The ECM is a complex mixture of various molecules like structural proteins (e.g. collagen, 
elastin), glycoproteins (e.g. laminin, fibronectin, and vitronectin), and proteoglycans (e.g. 
heparin sulfate, keratin sulfate, chondroitin sulfate). The cell adheres to the ECM and 
transmit signals via integrin receptors. Integrins are transmembrane cell adhesion 
molecules which act as matrix receptors and tie the ECM to the cell’s cytoskeleton and are 
composed of two noncovalently associated subunits: α and β (Figure 4). A variety of human 
integrin heterodimers are formed from 9 types of β subunits and 24 types of α subunits 
[93]. 
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Figure 4: The Structure of the Extracellular Matrix [94] 
1.5.1. ECM Interactions for Neuronal Differentiation 
The ECM constitutes a basal lamina (BL) that surrounds the brain and blood vessels of the 
CNS [95]. It has been shown that BL is crucial for the development of the neocortex and 
its removal results in the detachment of the radial glial cells (RGC) fibers that eventually 
affects the RGC survival and lamination of the cortex. Laminins are major constituent of 
the BL and is also found in the ventricular zone of the developing neocortex [96]-[97]. 
Laminins promote the expansion, migration, and differentiation of the neural stem cells in 
vitro and thus NSCs can be generated and differentiated into various phenotypes if Laminin 
is added exogenously [98]. 
1.6. Natural and Synthetic Substrate for Stem Cells Culture 
The hPSCs, derived from the inner cellular mass of the blastocyst hold a great interest in 
the clinical applications such as disease modelling, drug screening and toxicity testing, cell 
therapies [99], [100]. The traditional method of the hPSCs involves cell culture on mouse 
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fibroblast feeder layers with animal conditioned media or on Matrigel, an animal derived 
component that is rich in the ECM components essential for the growth [101]. Thus, these 
cultures not only possess an inherent risk of pathogen contamination but also the presence 
of the immunogenic epitopes [102].  
Natural Substrates: As discussed above, hPSC expansion on feeder free cultures involve 
Matrigel that constitutes the basement membrane and consists of collagen, laminin, heparin 
sulfate, metalloproteinases, etc [103], [104].  Matrigel has been used to study the long term 
expansion of hESCs upto 40 passages [105] and to study the effects of bone morphogenic 
protein 4 (BMP4) on the differentiation of hESCs [106]. Various synthetic substrates for 
hPSC cultures have been considered as an alternative to Matrigel due to its unsuitability 
for quality control, large scale production with current good manufacturing practicesof 
hPSCs as it shows batch-to-batch variability and xenogenic origin. Laminin provides 
adequate growth of hESCs through α6β1 integrins as these are major types of integrins 
present on the surface of hESCs. Various recombinant of Laminin have been derived but 
they show relatively less attachment and proliferation of hPSCs as these isoforms had more 
affinity for other integrins α3β1, α7β1 [107], [108]. Vitronectin binds to the αVβ5 integrins 
on cells via the RGD sequence. Braam et al showed that the recombinant vitronectin is as 
effective as the naturally purified vitronectin for hESC expansion and proliferation [109]. 
Heng  et al examined the scale up potential of vitronectin and laminin coated polystyrene 
microcarriers for 3D suspension cultures to 2D culture systems on tissue culture treated 
polystyrene (TCPS)  plates [110]. Table 1 rightly sums up the advantages and 
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disadvantages of these natural substrates and various other synthetic substrates that have 
been actively used for hPSC culture [111]. 
Table 1. Advantages and Disadvantages of Natural and Synthetic Substrates [111]. 
Substrate Advantages Disadvantages 
Matrigel Allows feeder-free cell 
culture 
Inexpensive 
Long-term hESCs culture 
Xenogeneic origin 
Undefined components 
Pathogenic contamination 
risk 
Immunogenic epitope 
Batch-to-batch variability 
Vitronectin 
 
 
 
Long-term hESCs culture 
αVβ5 integrin receptor 
mediated cell attachment 
Degradation upon 
sterilization 
Not-Scalable 
High production cost 
Synthetic peptides No batch-to-batch variation 
Immunogenicity risk 
avoided since chemically 
synthesized 
Scalable hPSCs culture 
Sterilization difficulties 
Labor intensive cell 
passaging 
Limited scale-up potential 
of 2D platform 
Synthetic Polymers Inexpensive Limited scale-up potential 
of 2D platform 
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Synthetic substrates: The protein based substrates like vitronectin, laminin, and fibronectin 
coated tissue culture plates have an advantage of being feeder free but they are not xeno-
free because they are usually animal derived. Thus they pose a great chances of significant 
immunogenic and pathogenic responses. Due to which these substrates cannot be used for 
the culture of stem cells in clinical applications. Consequently, peptide and polymer based 
substrates can act as better alternative for the culture of hPSCs.  
Heparin binding peptides have known to promote cell adhesion and interaction with cell 
through their cell-surface glycosaminoglycans (GAGs) which are mainly involved in cell-
cell adhesion and recognition and, cell-ECM interaction. In an earlier study for determining 
the optimal peptides for the culture of hESC, Klim et al. showed different heparin bbinding 
peptide surfaces that were vitronectin derived and supported the expansion, adhesion and 
self-renewal of the hESCs [111]. 
1.7. Scale up Expansion of Stem Cells 
HPSCs have two basic characteristics, first being the self-renewal i.e. they can divide 
indefinitely, second is pluripotency i.e. they can be differentiated into all cell types of a 
mature human body. It has been shown that human neural progenitor cells (hNPCs) can be 
generated from hPSCs by the addition of various inhibitors of bone morphogenic pathways 
such as Noggin and Dorsomorphin. hNPCs holds great potential in various clinical 
applications such  as disease modelling, cell therapy, drug screening and testing [112]. 
These clinical applications require substantially higher number of cells.  The traditional 
method of long term expansion and differentiation of hNPCs relies on 2D tissue culture. In 
this, the surface area for cell expansion is limited and multistep medium feedings, replating 
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and cell selection is required for differentiation. On the other hand, microcarrier suspension 
cultures have shown to be a great approach for culturing hNPCs in higher numbers. 
Microcarriers provide higher surface area to volume ratio and enable the use of stirred 
culture systems that result in higher folds cell expansion in comparison to 2D static plates 
[113].  
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CHAPTER 2: MATERIAL AND METHODS 
2.1. Overview 
 In this study, we characterized the ECM and cell surface integrin profile of hNPCs 
to rationally design peptide-based substrates for the growth and differentiation of hNPCs. 
Of the peptides tested, we identified one 14 amino acid long peptide derived from the cell-
binding domain of vitronectin [117] that provides for the expansion and neuronal 
differentiation of hNPCs. Moreover, this peptide, referred to as vitronectin-derived peptide 
(VDP), is easily coated onto tissue-culture treated polystyrene (TCPS) plates and 
microcarriers and supports the long-term propagation and directed neuronal differentiation 
of multiple hNPC lines in completely defined medium conditions. Overall, VDP is a 
completely defined and scalable substrate that support the long-term expansion and 
directed neuronal differentiation of hNPCs in quantities necessary for their scientific and 
clinical applications.  
2.2. Differentiation of Neural Progenitor Cells from hPSCs in 2D Cultures. 
2.2.1. HPSCs Expansion 
The hPSCs (HES-3, H-9 and RiPSCs) were cultured in feeder free conditions i.e. tissue 
culture treated plates coated with Matrigel for a minimum of two passages. The media for 
the hPSC culture comprise essential 8 (E8) components: (1x DMEM F-12 (Life 
Technologies), NAHCO3 (543 µg/mL, Invitrogen), L-Ascorbic acid-2 phosphate 
(64µg/ml, Sigma), Sodium selenite……). Upon 70% confluency cells, the media as 
aspirated out and Accutase (EMD Millipore) was added. The plates were incubated for 5 
minutes to allow cell detachment. The accutase was inactivated by adding equal volume of 
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cell media to the cell suspension solution. The cells were pelleted down by centrifugation 
at 200 g for 5 minutes. The cells were resuspended in E8 media and 5 µM ROCKi, Y-
267632 (EMD Millipore) and were counted using Hemocytometer. The cells were then 
plated at the desired densities based on the size of the culture plates for hPSC expansion or 
used for Embryoid body formation. 
2.2.2. Embryoid Body Formation 
The suspended hPSCs cells were dissociated in  neural induction media [1xDMEM-12, 1% 
(v/v) N2 supplement (Life Technologies), 1% (v/v) B-27 supplement (Life Technologies), 
50 ng/ml recombinant mouse Noggin (R&D Systems), 0.5 µM Dorsomorphin (Tocris 
BioScience), 1% penicillin/streptomycin (Life Technologies)] and 5 µM ROCKi, Y-
267632. 1-2 x 106 cells were pipetted to each well of a 6-well ultra low attachment plate 
(Corning). The plates were then placed on an orbital shaker set at 95 rpm in a 37OC/5% 
CO2 tissue culture incubator. The next day, the cells formed spherical cultures (embryoid 
bodies [EBs]) and the media was changed to neural induction media without ROCKi. The 
EBs were cultured in suspension for 5 days in the same plate with half media change for 
every other day.  
2.2.3. Neural Rossette Formation 
After culturing in suspension for 5 days, the EBs were then transferred to a 10 cm dish (1-
2 6 wells per 10 cm dish) coated with Matrigel. Most of the EBs adhere to the surface after 
one day of seeding. The plated EBs were cultured in neural induction media for 5-7days. 
Over time they form these rosettes like structures. The media was changed every other day.  
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The neural rosettes were dissected manually into single cells under an EVOS (Life 
Technologies) microscope using 1 ml pipette after incubation with Accutase for 5 minutes. 
2.2.4. Neural Progenitor Cell (NPC) Culture and Expansion 
The neural rosettes dissected from above were then centrifuged at 200g for 5 minutes. The 
cell pellet was then suspended in the NPC expansion media [NEM; 1x DMEM/F12, 1% 
B27 supplement, 1% N2 supplement, 1% Gluta-MAX, 1% penicillin/streptomycin]. The 
dissociated cells were then plated onto poly-L-ornithine (PLO; 4μg/mL; Sigma) and mouse 
laminin (Ln; 4 μg/mL; Life Technologies) coated dishes in NEM supplemented with 30 
ng/ml mouse FGF2 and 30 ng/ml mouse EGF2 (R&D systems). For routine maintenance, 
the human pluripotent stem cell derived NPCs (hNPCs) were cultured onto PLO/Ln coated 
plates at a density of 1-5 x 104 cells/cm2 and passaged upon 90% confluency.  
2.2.5. Neuronal Differentiation 
The hNPCs were grown to confluency and the media was changed to neuronal 
differentiation media [NDM; 1X DMEM-F12, 0.5% (v/v) N2 supplement (Life 
Technologies), 0.5% (v/v) B27 supplement (Life Technologies)] with 20 ng/ml BDNF 
(R&D Systems), 20 ng/ml GDNF (R&D Systems), 1 μM DAPT (Tocris Bioscience), and 
0.1 mM dibutyrl-cAMP (db-cAMP)]. The hNPCs were then cultured for up to four weeks 
and half media was changed every day with NDM. The neuron like structures were visible 
from day 5-6 itself (Figure 5).  
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Figure 5. Differentiation of hPSCs into hNPCs and Neurons 
2.3. HNPC Culture and Neuronal Differentiation on Peptide Substrates 
The VDP peptide was custom synthesized by AnaSpec. Peptide surfaces were prepared by 
reconstituting lyophilized peptide in sterile water and coating multi-well plates overnight 
at 37OC. Peptide-coated plates were washed twice with PBS prior to culture. HNPC culture 
and neuronal differentiation was performed in a similar manner as described for PLO/LN-
coated surfaces. 
2.4. VDP Labeling with F-5-M 
The coating of the VDP on TCPS was assessed by labelling the peptide with a fluorescent 
dye Fluorescein-5-Maleimide (F-5-M). F-5-M, at a final concentration of 1 mM was added 
to peptide concentrations 0.1 mM, 0.075 mM, 0.05 mM, 0.025 mM, and 0.01 mM in a 
multiwell plate. The positive control was 1x DPBS and 1mM F-5-M. The solutions were 
incubated overnight at 37oC, protected from light. Later, the coated wells were washed 
twice with 1x DPBS. The fluorescence of the surfaces was visualized in the fluorescence 
microscope (Evos) at 488 nm filter.  
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2.5. Microcarrier Coating  
Microcarriers (MC) were purchased from Corning (Corning Enhanced Attachment 
Microcarriers). They were weighed down into aliquots of 200 mg in sterile environment. 
Each aliquot was reconstituted in 5 ml of 1x DPBS to make a stock concentration of 40 
mg/ml. From the stock, 20 mg of the microcarriers was aliquoted in an eppendorf and were 
coated with VDP (0.5mM) and PLO/Ln (0.01%/4µg/ml). The microcarriers were incubated 
overnight at 37oC.  
2.6. HNPC Expansion and Differentiation on Microcarrier Suspension Culture 
The PLO/Ln and VDP coated microcarriers were washed 2x with DPBS and 1x with 
culture media before seeding with hNPCs. 1.5 x 106 cells were seeded on 4 mg 
microcarriers, initially dissociated at a concentration 2mg/ml in cell repellent plates. The 
culture plates were kept static for 12 hours to allow maximum cell attachment on MC. 
Later, the MC concentration was diluted to 1mg/ml and a final volume of 4 ml Nculture 
was used. The plates were kept on shaker at 95 rpm thereafter.  Half media was changed 
every day and the cells were passaged upon confluency (Figure 6).  
For neuron differentiation, hNPCs were cultured on MC as mentioned above and on Day 
2 of culture, 75% media was changed from NEM supplemented with EGF and FGF to 
NDM. Thereafter, half media was changed with NDM for 4 weeks.  
2.7. Quantitative PCR (qPCR).  
RNA was isolated from cells using the NucleoSpin RNA Kit (Clontech). Reverse 
transcription was performed with qScript cDNA Supermix (Quanta Biosciences) or iScript 
RT Supermix (Bio-Rad). Quantitative PCR was carried out using TaqMan Assays or SYBR 
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green dye on a Bio-Rad CFX96 or CFX384 TouchTM Real-Time PCR Detection System. 
QPCR experiments run with TaqMan Assays was carried out using TaqMan Gene 
Expression Master Mix (Life Technologies). QPCR experiments run with SYBR green dye 
were carried out using iTaq Universal SYBR Green Supermix (Bio-Rad). For the QPCR 
experiments run with TaqMan® Assays a 10 min gradient to 95 °C followed by 40 cycles 
at 95 °C for 5 s and 60 °C for 30 s min was used. For QPCR experiments run with SYBR 
green dye, a 2 min gradient to 95 °C followed by 40 cycles at 95 °C for 15 s and 60 °C for 
1 min was used. The list of TaqMan® assays and primer sequences used is provided in 
Table 3 (Appendix A). Gene expression was normalized to 18S rRNA levels. Delta Ct 
values were calculated as Cttarget − Ct18s. Relative fold changes in gene expression were 
calculated using the 2− ΔΔCt method [156]. 
2.6. Immunofluorescence 
 Cultures were gently washed twice with stain buffer (BD Biosciences) prior to fixation. 
Cultures were then fixed for 15 min at room temperature (RT) with BD Cytofix Fixation 
Buffer (BD Biosciences). The cultures were then washed twice with staining buffer and 
permeabilized with BD Phosflow Perm Buffer II (BD Biosciences) for 30 min at 4OC. 
Cultures were then washed twice with stain buffer. Primary antibodies were incubated 
overnight at 4OC and then washed twice with stain buffer at RT. Secondary antibodies were 
incubated at RT for 1 hr. Antibodies used are listed in Table 4 (Appendix B). Nucleic 
acids were stained for DNA with Hoechst 33342 (2 μg/ml; Life Technologies) for 5 min at 
RT. Imaging was performed using an automated confocal microscope (Olympus Fluoview 
1000 with motorized state) or EVOS microscope (Life Technologies) 
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2.7. Flow Cytometry 
Cells were dissociated with Accutase for 5 min at 37OC, triturated, and passed through a 
40 μm cell strainer. Cells were then washed twice with stain buffer (BD Biosciences) and 
resuspended at a maximum concentration of 5 x 106 cells per 100 μl. For staining of 
extracellular membrane proteins, one test volume of antibody was added for each 100 μl 
cell suspension. Cells were stained for 30 min on ice, washed, and resuspended in stain 
buffer. For staining of intracellular proteins, cells were fixed for 10 min on ice with BD 
Cytofix Fixation Buffer (BD Biosciences). The cells were then washed twice with stain 
buffer and permeabilized with BD Phosflow Perm Buffer II (BD Biosciences) for 30 min 
on ice. Cells were then washed twice with stain buffer and one test volume of antibody was 
added for each 100 μl of cell suspension. Cells were stained for 30 min on ice, washed, and 
resuspended in stain buffer.  Cells were analyzed on a FACSCanto (BD Biosciences) or 
ACCURI C6 (BD Biosciences). Antibodies and isotype negative controls are listed in 
Supplementary Table 3. 
2.8. Population Doubling Time 
 Population doubling time of hNPCs was calculated using the following equation: PDT (h) 
= (T2 − T1) / (3.32 * [log(N2) − log(N1)]). 
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CHAPTER 3: RESULTS 
3.1. Identification of Defined Peptide-Based Substrates for the Expansion of hNPCs. 
We have previously developed a serum free protocol that allows for the robust generation 
of hNPCs from several hPSC lines [114]. Briefly, hNPCs were generated through the 
stepwise formation of embryoid bodies (EBs) and neuroepithelial-like rosettes. After 
manual dissection from EB-derived rosettes, hNPCs were replated and maintained as 
proliferative, multipotent cells. Expression of the neuroectoderm marker FGF5 and neural-
specific marker SOX1 increased during hNPC generation and peaked upon hNPC 
expansion (Figure 6A). Upon continuous culture with FGF2 and EGF on laminin (LN)-
coated surfaces, hNPCs proliferated extensively and maintained high levels of expression 
of SOX1 and NESTIN (Figure 6B).  Subsequent differentiation of NPCs to neurons was 
achieved through the withdrawal of FGF2 and EGF and addition of BDNF, GDNF, 
dibutyrl-cAMP (db-cAMP), and the Notch inhibitor DAPT. After four weeks of treatment, 
cells acquired a neuronal morphology and expressed high levels of the pan-neuronal 
markers microtubule-associated protein 2 (MAP2) and β-Tubulin-III (B3T; Figures 6C 
and 6D). 
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Figure 6. Differentiation of hESCs to Neural Progenitor Cells (NPCs) and Neurons. 
(A) Quantitative PCR analysis for expression of neuroectoderm related genes FGF5 and 
SOX1 during generated of H9-hNPCs (mean ± S.E.M). (B) SOX1 and NESTIN 
immunofluorescence of proliferating H9-hNPCs (scale bar = 200 μm). (C) Quantitative 
PCR analysis of mature neuronal markers MAP2 and B3T in H9-hNPC and neuronal 
cultures (mean ± S.E.M). (D) B3T immunofluorescence of neurons differentiated from 
proliferating H9-hNPCs (scale bar = 200 μm). 
 
 The extracellular matrix (ECM) is complex network of extracellular matrix proteins 
(ECMPs) and proteoglycans that provides a scaffold for cell adhesion and growth. Integrins 
are a family of cell surface receptors that mediate binding to the ECM [115, 116]. To 
rationally design a set of defined peptides that could mimic the ECM and promote the 
adhesion as well as growth of hNPCs, we measured the expression of levels of various 
integrins and components of the ECM in undifferentiated hESCs, hNPCs, as well as early 
endoderm (EN), mesoderm (ME), and ectoderm (EC) cell populations differentiated from 
hESCs (Figure 7).  
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Figure 7. Analysis of Extracellular Matrix Protein (ECMP), Proteoglycan, and 
Integrin Expression in hPSCs, hNPCs, and hESC-Derived Endoderm (EN), 
Mesoderm (ME), Ectoderm (EC). Quantitative PCR analysis for expression of integrins, 
ECMPs, and proteoglycans in H9 hPSCs, hNPCs, and transient EC, EN, ME cell 
populations differentiated from H9 hPSCs. The data is displayed in a heat map where black 
corresponds to minimum expression levels and red corresponds to maximum levels. For 
each gene analyzed, the expression levels were normalized to the sample with the highest 
expression level. 
 
This analysis revealed that several integrins, ECMPs, and proteogylcans were differentially 
expressed in hNPCs than the other cell populations examined. To confirm the expression 
of specific integrins in hNPCs, we used flow cytometry to measure the cell surface 
expression of several α- and β-integrin subunits in proliferating hNPCs (Figure 8). This 
analysis revealed that integrins α4 (ITGA4), β3 (ITGB3), β4 (ITGB4), β7 (ITGB7) were not 
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expressed on the cell surface of hNPCs. Integrin subunits α1 (ITGA1), α2 (ITGA2), α3 
(ITGA3), β5 (ITGB5) were expressed at low levels while integrin subunits α5 (ITGA5), α6 
(ITGA6), αν (ITGAV), β1 (ITGB1), β2 (ITGB2) were highly expressed by proliferating 
hNPCs. Collectively, these integrin subunits can form the heterodimers α1β1 (binds to 
collagen and laminin), α2β1 (binds to collagen and laminin), α3β1 (binds to collagen, 
laminin, and fibronectin), α5β1 (binds to fibronectin), α6β1 (binds to laminin), ανβ1 (binds 
to fibronectin), and ανβ5 (binds to fibronectin and vitronectin) [115]. 
 
Figure 8. Expression of Integrins on hNPC. Integrin α1-6,ν and β1-5,7 was measured in 
multipotent H9-hNPCs was analyzed by flow cytometry. Gates were determined using 
isotype controls. 
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Using this information about the specific ECM components and integrins that were 
highly expressed in hNPCs, we designed a library of peptides with sequences that mimic 
these ECM components or the active domains known to interact with these integrin 
heterodimers [117-136]  (Table 2).  
Table 2: List of Peptides used in this Study 
Peptide Sequence Integrins ECMP Reference 
1 CGGTWYKIAFQRNRK  α2β1, α6β1 Laminin α1 116, 117 
2 CIKLLI   α3β1 Laminin α1 118 
3 CGGRKRLQVQLSIRT  α5β1 Laminin α1 116,119 
4 CIKVAV  α3β1, α4β1, α6β1 Laminin α1  120-122 
5 CGGNRWHSIYITRFG  α6β1 Laminin α1 116 
6 CRYVVLPR α3β1 Laminin β1 123,124 
7 CRNIAEIIKDI α6β1 Laminin β2 125 
8 CDITYVRLKF  α6β1 Laminin ϒ1 126 
9 CGGKAFDITYVRLKF  α5β1, αvβ3 Laminin ϒ1 127 
10 CDIRVTLNRL  α6β1 Laminin ϒ1 126,128 
11 CTTVKYIFR  α6β1 Laminin ϒ1 126 
12 CKGGPQVTRGDVFTMP  α5β1, αvβ3, αvβ5 Vitronectin 129 
13 CGKKQRFRHRNRKG αvβ5 Vitronectin 117 
14 CGWQPPRARI  α4β1 Fibronectin  130,131 
15 CRGDS α5β1, αvβ3, αvβ5 Fibronectin 132 
16 CDRVRHSRNSIT  α5β1 Fibronectin 133 
17 CPHSRN  α5β1 Fibronectin 134 
18 CDGEA  α2β1 Collagen  135 
 
To test if these peptides could support the growth and adhesion of hNPCs, cells 
were seeded into 96-well plates coated with 500 μM of each peptide. LN-coated 96-well 
plates were used as positive controls. Cell morphology (Figure 9) and cell counts (Figure 
9B) were analyzed after 72 hrs. Of the 18 peptides tested, only four peptides allowed for 
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hNPCs to display a morphology and cell number similar to that of cells grown on laminin 
control surfaces—peptide 1 (laminin α1 derived, binds to integrins α2β1 and α6β1; [118, 
119]), peptide 10 (laminin γ1 derived, binds to integrin α6β1; [128, 130]), peptide 12 
(vitronectin derived, binds to integrins α5β1 and ανβ5; [131]), and peptide 13 (vitronectin 
derived, binds to integrins ανβ5: [117]). 
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Figure 9. Identification of Peptide-Based Surfaces for hNPC Adhesion and Growth.  
(A) Representative phase contrast images of H9-hNPCs cultured on laminin (LN)- or 
peptide-coated tissue culture plates for 72 hrs. All peptides were tested at a concentration 
of 0.5 μM. (B) Cell count of H9-hNPCs cultured on the LN or peptide-coated tissue culture 
plates for 72 hrs. Quantification of images was performed by counting 9 fields at 10x 
magnification. Cell counts were normalized to those on LN surfaces. Image quantification 
of the data is presented as the average of these fields ± standard deviation (S.D.). Cell 
counts on peptides were compared to cell counts on LN controls using Student’s t-test with 
Bonferroni correction (∗p < 0.05). The sequences of the peptides tested are listed in Table 
2. 
 
3.2. Long-term Expansion of hNPCs on Defined Peptide Surfaces 
We tested if the four ‘hit’ peptides that we identified to support the short-term growth of 
hNPCs could support hNPC proliferation and maintenance of multipotency over multiple 
passages. In addition, to investigate the broad utility of these ‘hit’ peptides, we performed 
this analysis with four hNPC lines derived from three independent hESC lines (H9 [137], 
HSF4 [138], and HES3 [139]) and one hiPSC line (RiPSC, [140]). We cultured hNPCs in 
12-well plates coated with various concentrations of each ‘hit’ peptide. Cell detachment or 
differentiation, as indicated by acquisition of a neuronal morphology, was observed within 
the first three passages on all peptides with the exception of peptide 13 (herein referred to 
as vitronectin-derived peptide [VDP]). In addition, a dose-response curve revealed that 100 
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μM of VDP was the minimum concentration necessary to promote hNPC adhesion at levels 
similar to that on LN-control substrates (Figure 10).  
 
Figure 10. Effect of VDP Concentration on Growth and Adhesion of hNPCs. (A) 
HES3-hNPCs were grown on surfaces coated with various concentrations of VDP. Cell 
counts were performed after 72 hrs of culture on the VDP-coated surfaces. Quantification 
of images was performed by counting 4 fields at 10x magnification. Image quantification 
of the data is presented as the average of these fields ± standard error of the mean (S.E.M). 
Cell counts were compared using Student’s t-test (∗p < 0.05). (B) Representative phase 
contrast images of HES3-hNPCs grown on surfaces with various concentration so VDP 
(scale = 250 μm). 
 
HNPCs cultured on VDP-coated substrates maintained their characteristic morphology 
over 10 passages (> 50 days; Figure 11A and Figure 12A). HNPCs cultured on VDP 
displayed a similar doubling time (Figure 11B and Figure 12B) to cells cultured on control 
LN substrates. In addition, the hNPC growth rate on VDP remained constant over the 
course of 10 passages (Figure 11C and Figure 12C). Cell counts taken at each passage 
revealed that 2 x 105 hNPCs could theoretically be expanded to 1 x 1011 over the course of 
10 passages (Figure 11C and Figure 12C).  
A 
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Figure 11. Long-term Expansion of hNPCs on VDP-Coated Surfaces. (A) 
Representative phase contrast images of H9-hNPCs cultured on LN and VDP surfaces for 
10 passages (scale bar = 500 μm). (B) Doubling time of H9-hNPCs cultured on LN and 
VDP (mean ± S.D). (C) H9-hNPCs were cultured on LN and VDP and cell growth was 
analyzed by cell count at each passage (mean ± S.E.M). 
LN VDP 
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Figure 12. Long term Expansion of hNPCs Grown over 10 Passages (A) Representative 
phase contrast images of HES3- (top panels), HSF4- (middle panels) and RiPSC-hNPCs 
(bottom panels) cultured on LN and VDP surfaces (scale bar = 500 μm).(B) Doubling time 
of RiPSC-hNPCs cultured on LN and VDP (mean ± S.D.) (C) RiPSC hNPCs were cultured 
on LN and VDP and cell growth was analyzed by cell count at each passage (mean ± 
S.E.M.). 
 
Quantitative RT-PCR (qPCR) showed that expression of genes associated with a hNPC 
phenotoype (SOX1, SOX2, NESTIN) was similar in hNPCs grown on VDP- and LN-coated 
surfaces for 10 passages (Figure 13 and Figure 14A and 14B).  
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Figure 13. Gene Expression Analysis of hNPCs Maintained on VDP for 10 Passages. 
Quantitative PCR analysis for expression of hNPC multipotency markers SOX1, SOX2, 
and NESTIN in H9-hNPCs cultured on LN and VDP for 1, 5, and 10 passages (mean ± 
S.E.M). There was no statistically significant (Student’s t-test, p>0.05) difference in 
expression of these genes between the hNPC populations. 
 
 
 
Figure 14. Quantitative PCR analysis for expression of hNPC multipotency markers 
SOX1, SOX2, and NESTIN in (A) HSF4- and (B) RiPSC-hNPCs cultured on LN and VDP 
for 10 passages (mean ± S.E.M). There was no statistically significant (Student’s t-test, 
p>0.05) difference in expression of these genes between the hNPC populations. 
 
Similarly, immunofluorescence (Figure 15A and Figure 16A) and flow cytometry (Figure 
15B and Figure 16B and 16C) demonstrated that a high percentage (>85%) of hNPCs 
cultured on VDP-coated surfaces expressed the hNPC markers SOX1, SOX2, and 
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NESTIN. Taken together, these results demonstrate that VDP is able to support the long-
term expansion of hNPCs at a similar level to control LN substrates. 
 
 
Figure 15. Protein Expression of hNPCs Maintained over 10 Passages. (A)  SOX1, 
SOX2, and NESTIN immunofluorescence of H9-hNPCs cultured on LN and VDP for 10 
passages (scale bar = 200 μm).  (B) Flow cytometry analysis for SOX1, SOX2, and 
NESTIN expression in H9 hNPCs cultured on LN and VDP for 10 passages. Gates were 
determined using isotype controls. Isotype controls used are listed in Supplementary 
Table 3. 
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Figure 16. Protein Expression of hNPCs Maintained over 10 Passages.  (A) SOX1, 
SOX2, and NESTIN immunofluorescence of RiPSC-hNPCs cultured on LN and VDP for 
10 passages (scale bar = 200 μm). Flow cytometry analysis for SOX1, SOX2, and NESTIN 
expression in (B) HSF4- and (C) RiPSC-hNPCs cultured on LN and VDP for 10 passages. 
Gates were determined using isotype controls. Isotype controls used are listed in Table 3. 
 
3.3. Characterization of hNPC Integrin Profile on VDP-Coated Surfaces 
We hypothesized that long-term culture of hNPCs on VDP-coated surfaces would lead to 
a shift in their integrin expression profile to one of increased expression of integrins known 
to directly bind to VDP (i.e. integrins αv and β5; [117]). To that end, we used qPCR to 
measure expression of integrins that we previously identified to be expressed by hNPCs 
cultured on LN substrates. Surprisingly, this analysis revealed no statistically significant 
differences in integrin expression between hNPCs cultured on VDP- and LN-coated 
surfaces (Figure 17). We speculate that continued expression of integrins that do bind 
directly to VDP may facilitate interaction with endogenous ECM components that are 
produced by hNPCs after their initial adhesion and subsequent growth.  
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Figure 17. Analysis of Integrin of hNPCs Cultured on LN- and VDP-Coated Surfaces. 
H9- and HSF4-hNPCs cultured on LN and VDP have similar integrin gene expression 
profiles. The data is displayed for the biological triplicates in a heat map where black 
corresponds to minimum expression levels and red corresponds to maximum levels. For 
each gene analyzed, the expression levels were normalized to the sample with the highest 
expression level. 
 
3.4. Neuronal Differentiation of hNPCs on VDP-Coated Surfaces 
We next assessed if VDP surfaces could support the neuronal differentiation of hNPCs. To 
that end, hNPCs were grown on VDP and LN control surfaces until they reached 
confluence and neuronal induction medium was added. After 4 weeks of differentiation, 
cells cultured on VDP and LN substrates acquired a neuronal-like morphology. QPCR 
analysis revealed that neuronal cultures on both substrates expressed similarly high levels 
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of the pan-neuronal markers β3T and MAP2 (Figure 18 and Figure 19). 
 
Figure 18. Gene Expression of hNPCs (HES-3) Derived Neurons on VDP-Coated 
Surfaces. Quantitative PCR analysis for expression of neuronal (B3T, MAP2). There was 
no statistically significant (Student’s t-test, p>0.05) difference between expression of these 
genes in hNPCs differentiated on VDP and LN substrates. 
 
Figure 19. Gene Expression of hNPCs (RiPSC) Derived Neurons on VDP-Coated 
Surfaces. Quantitative PCR analysis for expression of neuronal (B3T, MAP2). There was 
no statistically significant (Student’s t-test, p>0.05) difference between expression of these 
genes in hNPCs differentiated on VDP and LN substrates. 
 
 Along similar lines, immunofluorescence revealed that the percentage of cells that were 
positive for β3T, MAP2, neurofilament-68 (NF-L), and the neurotransmitter γ-
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aminobutyric acid (GABA) was similar in neuronal cultures generated on VDP and LN 
substrates (Figure 20A and Figure 21B). Finally, quantification of the raw number of β3T, 
MAP2, and NF-L positive cells revealed that VDP was an equally efficient differentiation 
substrate as LN (Figure 20B). Overall, these results demonstrate that VDP is a highly 
effective neuronal differentiation matrix for hNPCs. 
 
 
B 
A 
47 
 
Figure 20. Immunofluoresnce Staining of Neuron Differentiation on VDP Coated 
Surfaces. (A) Immunofluorescence of for B3T, NF-L, MAP2, and GABA on neurons 
differentiated from RiPSC-hNPCs on LN and VDP substrates (scale bar = 200 μM). (B) 
Cell counts of the number of B3T, MAP2, and NF-L positive cells in neuronal cultures 
generated from RiPSC-hNPCs on LN and VDP substrates. Quantification of images was 
performed by counting 3 fields at 20x magnification. Image quantification of the data is 
presented as the average of these fields ± S.E.M). There was no statistically significant 
(Student’s t-test, p>0.05) difference in the number of B3T, MAP2, and NF-L positive 
neurons generated on LN- and VDP-coated substrates. 
 
 
 
Figure 21. Neuronal Differentiation of Additional hNPCs on VDP-Coated Surfaces. 
(A) Quantitative PCR analysis for expression of neuronal markers B3T and MAP2 of 
neurons differentiated from HES3-hNPCs on VDP and LN substrates (mean ± S.E.M). 
There was no statistically significant difference (p>0.05) in B3T and MAP2 expression 
between hNPCs differentiated on VDP and LN substrates. (B) Immunofluorescence for 
B3T on neurons differentiated from H9-hNPCs on LN and VDP substrates (scale bar = 200 
μM). 
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3.5. Verifying the Attachment of VDP Coating  
To look at the coating chemistry, we labelled our VDP peptide with a fluorescent dye, 
fluorescein-5-maleimide (F-5-M). The F-5-M has a maleimide group which reacts with the 
Sulphur (-SH group) of the cystein which is present at the N terminal in the sequence. The 
maleimide forms a bond with the Cysteine through the carbon-sulphur bond thus 
conjugating the dye to the peptide (Figure 22A). To assess the labelling of the peptide, 
same amount of dye (1mM) was reacted with different concentrations. Maximum 
fluorescence was observed in the peptide concentration 1 mM followed by 0.075 mM, 0.05 
mM, and least in 0.025 mM. To further prove our results, no fluorescence was observed in 
our positive control (Figure 22B).   
 
Figure 22: VDP Labelling with F-5-M. A) The thiol-maleimide chemical reaction 
mechanism. The fluorescently labelled maleimide reacts with the thiol group of the 
cysteine and couples with it thereby attaching the fluorescent dye to the cysteine of the 
peptide. B) The fluorescent images of TCPS coated with F-5-M labelled VDP. The same 
amount of dye was added to different concentrations of VDP for labeling.  
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3.6. Long term expansion of hNPCs on VDP coated microcarrier suspension culture 
In order to create a xenofree scale up culture to meet the need of high cell numbers required 
for cell based therapies, drug screening and regenerative medicine, we seeded hNPCs on 
VDP coated microcarriers (MCs) in suspension culture. HNPCs cultured on VDP MC 
maintained their characteristic morphology over 10 passages (>50 days; Figure 23). 
HNPCs cultured on VDP displayed a similar doubling time (Figure 24) to cells cultured 
on the control LN coated MC. The hNPC growth rate on VDP MC remained constant over 
the course of 10 passages (Figure 16C). Cell counts at each passage revealed that 1.5x106 
hNPCs could theoretically be expanded to 1x1012 over the course of 10 passages (Figure 
16D). Quantitative RT-PCR (qPCR) showed that expression of genes associated with 
hNPC phenotype (SOX1, SOX2, NESTIN) was similar in hNPCs grown on VDP and Ln 
coated surfaces for 10 passages. This gene expression was further compared with the 
hNPCs grown on VDP and Ln in 2D static cultures and we found that there was no 
significant difference in the expression of these markers in any of the passages in 2D static 
and MC suspension cultures (Figure 25).  
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Figure 23: Phase Contrast Images of hNPC Culture on VDP Coated MC. Cell 
morphology of hNPCs on LN and VDP coated microcarriers. The upper row shows images 
of hNPCs on Day 1 and lower row shows the images of hNPCs upon confluency. 
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Figure 24: Growth rate Analysis of hNPCs Grown on LN and VDP Microcarrier. A) 
RiPSC hNPCs cultured on LN and VDP and cell growth was analyzed by cell count at each 
passage (mean ± S.E.M.). (B) Doubling time of RiPSC-hNPCs cultured on LN and VDP 
(mean ± S.D.) hNPCs grown on VDP and LN MC maintain similar growth rate over the 
course of 10 passages.  
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Figure 25: Gene Expression of hNPCs Derived on VDP Coated Microcarrier. 
Quantitative PCR analysis for expression of hNPC multipotency markers NESTIN, SOX1, 
and SOX2 in RiPSC-hNPCs cultured on LN and VDP MC suspension culture for 1,  5 and 
10 passages on 2D and MC suspension culture (mean ± S.E.M). There was no statistically 
significant (Student’s t-test, p>0.05) difference in expression of these genes between the 
hNPC populations. 
 
Similarly immunofluorescence and flow cytometry (Figure 26) demonstrated that a high 
percentage (>90%) of hNPCs cultured on VDP MC expressed hNPC markers SOX1, 
SOX2, and NESTIN. Thus, summing up these results demonstrate that VDP MC is able to 
support the long-term expansion of hNPCs at a similar level to control LN substrates.   
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Figure 26. Protein Expression of hNPCs Maintained over 10 Passages. (A)  SOX1, 
SOX2, and NESTIN immunofluorescence of RiPSC-hNPCs cultured on LN and VDP MC 
(scale bar = 200 μm).  (B) Flow cytometry analysis for SOX1, SOX2, and NESTIN 
expression in RiPSC hNPCs cultured on LN and VDP coated MC suspension culture for 6 
passages. 
 
3.7. Neuronal Differentiation of hNPCs on VDP coated MC suspension culture 
We wanted to assess if the VDP coated MC suspension culture could support the neuronal 
differentiation of hNPCs. So the hNPCs were cultured on VDP and LN coated MC in 
suspension and upon confluency, the media was switched with neuronal differentiation 
media (NDM). After 4 weeks of differentiation, the cells were stained positive for β3T and 
neurofilament-68 (NF-L) on VDP coated Mc suspension cultures (Figure 27). Hence, these 
results demonstrate that VDP is a highly effective and robust neuronal differentiation 
matrix for hNPCs even in MC suspension cultures 
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Figure 27. Protein Expression of RiPSC Neurons on VDP Coated Microcarrier 
Suspension Cultures. β3T and  neurofilament-68 (NF-L) Immunofluorescence of RiPSC 
neurons differentiated on VDP coated MC suspension cultures (Scale bar = 200 um).  
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CHAPTER 4: DISCUSSION 
The application of hNPCs for scientific and clinical purposes necessitates the 
engineering of completely defined and scalable substrates that support their long-term 
expansion and directed neuronal differentiation. In this study, we identified one peptide-
based substrate, VDP, which was able to support the long-term growth of several 
independently derived hNPC lines over multiple passages in defined medium conditions. 
Compared to hNPCs cultured on ECMP-based LN substrates, hNPCs grown on VDP-
coated surfaces displayed similar morphologies, growth rates, and high expression levels 
of hNPC multipotency markers. Furthermore, VDP surfaces supported the directed 
differentiation of hNPCs to neurons at similar level to cells differentiated on LN substrates.  
 Laminin from tissue purified or recombinant sources is the most commonly used 
substrate for the growth and differentiation of hNPCs. The use of LN as a substrate for 
hNPC culture is largely based on previously developed methods for the propagation of 
primary fetal and adult neural stem cells (NSCs) [141], which express high levels of the 
LN binding integrins α6 and β1 [142]. However, we found that only two (peptide 1 and 
peptide 10) of the eleven peptides derived the cell binding domains of LN or known to 
interact with LN-binding integrin heterodimer α6β1 supported the attachment of hNPCs and 
none were able to support the long-term growth of hNPCs. Our integrin expression 
profiling revealed that in addition to these LN binding integrins, hNPCs also expressed 
high levels of integrins that bind other ECMPs such collagen (i.e.  α1, α2, α3), fibronectin 
(i.e. α5) and vitronectin (i.e. αν, β5). Nonetheless, peptides derived from these integrin 
binding domains of collagen and fibronectin did not support the attachment of hNPCs. The 
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two peptides (VDP and peptide 12) derived from vitronectin that we examined were able 
to support the attachment of hNPCs but only VDP was able to support the long-term culture 
of hNPCs. Previous studies have demonstrated that VDP not only mediates cell binding 
through interactions with integrin ανβ5 but also cell surface proteoglycans [117]. 
Interestingly, our analysis revealed that in addition to expressing high levels of integrins 
αν and β5, hNPCs also express high levels of several proteoglycans including decorin 
(DCN), fibrillin (FBN1), fibromodulin (FMOD), heparan sulfate proteoglycan (HSGP2), 
and lumican (LUM). Therefore, we speculate the dual ability of VDP to bind to both 
integrin ανβ5 as well as cell surface proteoglycans highly expressed by hNPCs allowed for 
VDP to support the long-term expansion of hNPCs.  
 Previously, peptide-based materials have been used for the expansion and 
differentiation of hPSCs [143,144]. Specially, a similar peptide sequence that served for 
the basis for VDP in this study has been used for the long-term culture of undifferentiated 
hPSCs [27]. More recently, surfaces displaying this same peptide sequence supported the 
differentiation of hPSCs to early endoderm and mesoderm cell types. Interestingly, 
surfaces displaying similar peptide sequences to VDP only supported the ectodermal 
differentiation of hPSCs when those surfaces also displayed a cyclic-RGD containing 
peptide. Our analysis revealed several RGD binding integrins, such as integrin α5, were 
expressed at significantly higher levels in early hESC-derived ectoderm cells than in 
proliferating hNPCs possibly explaining the need for both peptide sequences for the 
differentiation of hESCs to early ectoderm cell types. Another broadly used peptide-based 
material, Corning® Synthemax®, has been used for the long-term culture of hPSCs [24] 
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as well as their differentiation into retinal pigmented epithelial cells [21], mesenchymal 
stem cells [22], oligodendrocyte progenitor cells [23], cardiomyocytes [24], and insulin 
producing cells [25]. In this study, we tested the same peptide sequence (peptide 12) that 
serves as the basis for Corning® Synthemax®. Although this peptide was able to support 
the attachment and short-term expansion of hNPCs, it did provide for the expansion of 
hNPCs over multiple passages. Moreover, Synthemax® plates purchased directly from 
Corning® were unable to support the long-term growth of hNPCs (data not shown).  
 Several groups have reported the use of peptide-based substrates for the short-term 
expansion of primary NSCs [59, 60]. For example, Li et al. reported the use of laminin 
derived IKVAV peptide conjugated to gold-coated cover slips for the short-term growth 
and neuronal differentiation of immortalized human fetal NSCs [145]. Along similar lines, 
Little et al. identified several RGD-based peptide surfaces that allowed for the adhesion, 
growth and differentiation of adult rat hippocampal NSCs [146]. In this study, peptides 
containing IKVAV (peptide 4) and RGD (peptide 15) were unable to support the 
attachment and growth of hNPCs. Although NSCs derived from fetal [147-150] and adult 
[151-154] sources share some morphological, biochemical, and genetic similarities to 
hPSC-derived hNPCs, several studies have shown that the growth conditions and 
differentiation potential of these two cell populations are quite different. These subtle 
biological differences could potentially explain why peptide surfaces that have been 
previously used for the culture of NSCs did not support the long-term culture of hNPCs. 
The development of robust, defined, and scalable substrates for hNPC culture and 
differentiation are necessary to realize their scientific and clinical potential.  In this study, 
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we demonstrate that VDP is a robust growth and differentiation matrix, as demonstrated 
by its ability to support the expansions and neuronal differentiation of hNPCs derived from 
three hESC (H9, HUES9, and HSF4) and one hiPSC (RiPSC) cell lines. In addition, similar 
to hNPCs grown on LN cells expanded on VDP can be frozen and thawed without any 
detectable effects on their morphology, growth, and differentiation potential. Furthermore, 
similar to ECMPs, VDP can be easily coated onto TCPS plates and microcarriers, and does 
not require immobilization by complex chemical modification or conjugation characteristic 
of other peptide-based culture systems [159]. Finally, in this study we show that VDP 
allows for the theoretical expansion of hNPCs to quantities, >1010 in 2D culture system and 
>1012 in microcarrier suspension cultures, necessary for drug screening or regenerative 
medicine. In the future, VDP could potentially be used in microcarrier-based bioreactor 
systems [155] for the practical large-scale expansion and neuronal differentiation of 
hNPCs. 
In the second half of this study we showed that VDP also allows for scalable long term 
expansion of hNPCs when cultured in microcarrier suspension culture system. The average 
cell count that we generated in this 4 ml suspension culture was 5.8 million cells and the 
cell count achieved in the 2D system of similar surface ara as the microcarrier culture well, 
we get 2 million cells. If we are to scale up this microcarrier suspension culture to a 
bioreactor system of 500 ml culture volume and 20mg/ml microcarrier density [159], we 
would be able to generate about 60 billion cells from each culture which is y more than the 
cell number required for cell based therapies (~1 billion cells). 
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CHAPTER 5: CONCLUSIONS 
In this study, we developed a completely defined, scalable, and robust peptide-based 
substrate that allows for the long-term growth and directed neuronal differentiation of 
hNPCs. Compared to cells grown on standard LN-based substrates, hNPCs grown on VDP 
maintained their characteristic morphology, expressed high levels of hNPC multipotency 
markers, and retained their neuronal differentiation potential. In the future, the use of VDP 
as a defined culture substrate will significantly advance the clinical application of hNPCs 
and their derivatives as it will enable the large-scale expansion and neuronal differentiation 
of hNPCs in quantities necessary for disease modeling, drug screening, and regenerative 
medicine applications. 
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APPENDIX A 
LIST OF QPCR PRIMERS USED IN THIS STUDY 
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Gene ABI Assay 
18s Hs99999901_s1 
MAP2 Hs00258900_m1 
NES Hs00707120_s1 
SOX1 HS01057642_s1 
SOX2 Hs01053049_s1 
B3T Hs00801390_s1 
NANOG Hs04399610_g1 
OCT4 Hs00999632_g1 
FOXA2 Hs00232764_m1 
SOX17 Hs00751752_s1 
MESP1 Hs01001283_g1 
T Hs00367969_m1 
 
Gene Forward Reverse 
Product 
(bp) 
ITGA1 CTCACTGTTGTTCTACGCTGC AACATGTCTTCCACCGGGC 86 
ITGA2 GGTGCTCCTCGGGCAAATTA GAGCCAATCTGGTCACCTCG 104 
ITGA3 CCCACCTGGTGTGACTTCTT CTGGTCACCCAGTGCTTCTT 137 
ITGA4 TTTATGCGGAAAGATGTGCGG ATTGGCTGAAGTGGTGGGAA 119 
ITGA5 AAGACTTTCTTGCAGCGGGA GCCACCTGACGCTCTTTTTG 122 
ITGA6 GCAGCCTTCAACTTGGACAC CACGAGCAACAGCCGCTT 129 
ITGA7 TCGAACTGCTCTTCTCACGG CCACCAGCAGCCAGCTC 147 
ITGA8 ATCCTCAGGAAACTGGCAGG CAGCAACTGAGTATCCAAGGT 85 
ITGAV AGGGTCTTTCTACCTCTGCCT GAAGAAACATCCGGCACAACA 156 
ITGB1 CCGCGCGGAAAAGATGAATTT CCACAATTTGGCCCTGCTTG 150 
ITGB2 CCAAGGAGGAGCTGAGAGGA CCAGCATGTCCCTCGGTG 157 
ITGB3 ACTGGCAAGGATGCAGTGAA TTGGGACACTCTGGCTCTTC 125 
ITGB4 CACATCCTCCACCCTCACAC CAGTCAGGCGAGAGTCGTG 125 
ITGB5 CTGCATCCAACCAGATGGACTA ATCTCCACCGTTGTTCCAGG 151 
ITGB7 TGCCGTCTCCCAGATCAGTA GTTTCCACATAGGTGCGTGC 79 
BGN CACCGGACAGATAGACGTGC CATGGCGGATGGACCTGGAG 96 
COL1A1 GGGACACAGAGGTTTCAGTGG CACCATCATTTCCACGAGCA 185 
COL3a1 TAAAGGCGAAATGGGTCCCG GGCACCATTCTTACCAGGCT 136 
COL4A1 CCGTGGGACCTGCAATTACT CGGCGTAGGCTTCTTGAACA 88 
COL5A1 CTTGGCCCAAAGAAAACCCG CGTCCACATAGGAGAGCAGT 72 
COL5a2 GGAAGAAGACGAGGATGAAGGAT ACACAGATCTGACAAGGGGC 108 
COL12a1 AGATCTCTTCATGCCGCTGT TGGGTCAACTTCTGCCTCAAT 118 
COL14a1 CAGGACCTTCAGGGGAGAGT ATGGGGAGCTCTCACACCATA 167 
DCN GGGAGCAGAGAAGAGGGAGA TCACAACCAGGGAACCTTGC 117 
DPT GTGATAGTGGCCGTGAGGAG GCACGTCTGGTACCATTCCA 156 
ECM1 CTGCTCACACATTCCCCCTT GGGGGACCCACTTCCTTTTC 117 
ECM2 CAACAAAGCTGTGTGGTCGC ATAGGAGACAGTAGCGGAGCA 157 
FN1 ACAAACACTAATGTTAATTGCCCA CGGGAATCTTCTCTGTCAGCC 74 
FBN1 ACGTGAAGGAAACCAGAGCC GCCGGCAAATGGGGACAATA 162 
FMOD AACTTGAGAGACAAAATGCAGTGG TAGTAGGTGGACTGCTGGCT 131 
78 
 
HAPLN1 GAGAGCATCCGAACTCCTGG GGGGCCATTTTCTGCTTGGA 173 
HSPG2 GCAGGAGGCTTCGTTTTGC ATGTCAGCTCTGCTCTCGACT 139 
LN CCGGTCCTCGCAGAGTTG CGTCTTCCTTTCCGGCGAC 171 
LUM CAGTAAGGATTCAAACCATTTGCCA ACTTGGGTAGCTTTCAGGGC 175 
NID1 GTTCCTTCATGTCCCGGCTA ACAGCGATACCTTCTGGACT 171 
POSTN CCCCGTGACTGTCTATAAGC CCTTGGTGACCTCTTCTTGTAA 197 
PLC TCTCATCCCAGGGTGACAGT GTTGTGGGACGAGCTCAAGG 160 
TNC CACAGCCACGACAGAGGC AAAGGCATTCTCCGATGCCA 103 
VTN GTGCAAGCCCCAAGTGACTC CCTCGCCATCGTCATAGACC 77 
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APPENDIX B 
LIST OF ANTIBODIES USED IN THIS STUDY 
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Antibody Vendor Catalog # 
Concentration 
Used 
Goat anti-SOX2 Santa Cruz SC-17320 1:50 
Mouse anti-B3T Fitzgerald 10R-T136A 1:1000 
Mouse anti-NESTIN BD 560341 1:10 
Mouse anti-SOX1 BD 560749 1:10 
Mouse anti-NF-L Sigma N5139 1:500 
Rabbit anti-MAP2 Millipore AB5622 1:500 
Rabbit anti-GABA Millipore AB15415 1:200 
Alexa-647 Mouse Anti-SOX2 BD 560294 20 µl per test 
PE Mouse anti-Nestin BD 561230 5 µl per test 
PerCp-Cy5.5 Mouse anti-SOX1 BD 561549 5 µl per test 
PE anit-CD49a/ITGA1 BioLegend 328303 5 µl per test 
PE anti-CD49b/ITGA2 BioLegend 359307 5 µl per test 
PE anti-CD49c/ITGA3 BioLegend 343803 5 µl per test 
PE anti-CD49d/ITGA4 BioLegend 304303 20 µl per test 
PE anti-CD49e/ITGA5 BioLegend 328009 5 µl per test 
PE anti-CD49f/ITGA6 BioLegend 313611 20 µl per test 
PE anti-CD51/ITGAV BioLegend 327909 5 µl per test 
PE anti-CD29/ITGB1 BioLegend 303003 5 µl per test 
Alexa Fluor 647 anti-
CD18/ITGB2 
BioLegend 101414 5 µl per test 
PE anti-CD61/ITGB3 BioLegend 359307 5 µl per test 
PE anti-CD104/ITGB4 BioLegend 327807 5 µl per test 
PE anti-ITGB5 BioLegend 345203 5 µl per test 
PE anti-ITGB7 BioLegend 121005 5 µl per test 
Alexa-647 Mouse IgG2a 
Isotype Control 
BD 558053 20 µl per test 
PE Mouse IgG1 Isotype Control BioLegend 400113 5 µl per test 
PE Mouse IgG2a BioLegend 400213 5 µl per test 
PE Mouse IgG2b Isotype 
Control 
BioLegend 400313 5 µl per test 
PE Rat IgG2a Isotype Control BioLegend 400507 5 µl per test 
PercCp-Cy5.5 MouseIgG1 
Isotype Control 
BD 550795 5 µl per test 
Alexa 647 Rat IgG2a Isotype 
Control 
BioLegend 400526 5 µl per test 
Alexa 647 Donkey anti-Goat Life Technologies A-21447 1:200 
Alexa 647 Donkey anti-Mouse Life Technologies A-31571 1:200 
Alexa 647 donkey anti-Rabbit Life Technologies A-31573 1:200 
Alexa 488 Donkey Anti-Goat Life Technologies A-11055 1:200 
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Alexa 488 Donkey Anti-Mouse Life Technologies A-21202 1:200 
Alexa 488 donkey anti-Rabbit Life Technologies A-21206 1:200 
 
